Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum

Core Insights - AbbVie Inc. is recognized as one of the 15 Best S&P 500 Dividend Stocks to Buy in 2026 [1] - Berenberg has increased its price target for AbbVie to $275, citing strong growth potential for Skyrizi and Rinvoq [2] - AbbVie has entered a three-year agreement with the Trump administration to lower drug prices in the US and will invest $100 billion in US-based R&D over the next decade [2][3] Investment Outlook - The growth trajectory for AbbVie's drugs, particularly Skyrizi and Rinvoq, is described as "exceptional," leading to increased confidence from analysts [2] - The investment will also support manufacturing expansion and the development of the direct-to-patient platform, TrumpRx, which will provide commonly used medications through AbbVie's own websites [3] - The agreement includes exemptions from tariffs and future pricing mandates, although specific details remain confidential [3] Market Context - The TrumpRx platform may primarily benefit those paying out of pocket, as most insured Americans already have set co-pays or co-insurance tied to list prices [4] - AbbVie is a major global biopharmaceutical company focused on a wide range of therapeutic areas, supported by extensive research, manufacturing, and commercialization operations [4]